Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2012

View Archived Issues

Identification of biological markers to distinguish MCI from early-stage AD

DiaGenic announces improved blood test to detect Alzheimer's disease

Boehringer Ingelheim presents novel B-raf inhibitors

German researchers design new mGlu5 receptor modulators

Hong Kong researchers patent new agents for cancer

Sarepta's lead candidate for Marburg virus improves survival in primates

The Medicines Company patents new agents for thrombotic disorders

Phase III study of brivanib in HCC does not meet primary endpoint

Abbott offers overview of second quarter 2012

Sigma-Tau presents new HSP 90 inhibitors

New metabotropic glutamate receptor antagonists synthesized at Novartis

Novartis highlights achievements of second quarter 2012

Agilent enters biomarker discovery collaboration with Gachon University of Medicine and Science

FDA grants accelerated approval to Onyx' Kyprolis for injection in treatment of multiple myeloma

SEARCH trial shows no overall survival improvement with addition of Tarceva to Nexavar in HCC

EMA committee recommends approval of Adcetris for two lymphoma indications

Yichang Humanwell obtains license to remimazolam in China from Paion

Investigators develop novel ischemia-reperfusion model in human placenta

CHMP recommends conditional approval of crizotinib

Meiji Seika Pharma to discontinue development of schizophrenia drug candidate

Piramal receives clearance in India to conduct P-276 study

EB-101 shows efficacy in animal models of AD

EMA committee recommends approval of first gene therapy

Phase III study in breast cancer begins for novel micellar nanoparticles

FDA approves Afinitor in combination with exemestane in advanced breast cancer

Janssen submits application for new formulation of anti-HIV agent in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...